Abstract：
UNASSIGNED: Despite potential benefits and widespread prescription of aspirin among chronic obstructive pulmonary disease (COPD) patients, limited research has investigated its adverse effects (AEs) in COPD population.
UNASSIGNED: We conducted a retrospective analysis of adverse drug events (ADEs) reported in the US Food and Drug Administration Adverse Event Reporting System (FAERS) between Q1 2013 and Q2 2022. COPD patients were categorized into two groups based on aspirin use. ADEs related to aspirin use were identified using combined reporting odds ratio (ROR), proportional reporting ratio (PRR), information component (IC) methods.
UNASSIGNED: A total of 56,660 ADEs reports associated with COPD patients were included in the study. Among these reports, 144 adverse events were linked to aspirin use in COPD patients, including fatigue (4.12%), diarrhea (3.13%), dyspnea exertional (2.03%), rhinorrhea (1.99%), weight increased (1.89%) and vomiting (1.84%), muscle spasms (1.79%), cardiac disorder (1.74%), heart rate increased (1.69%) and peripheral swelling (1.59%). Subgroup analysis indicates that age and gender might affect the AEs frequency in COPD patients using aspirin.
UNASSIGNED: Our findings identify 10 most frequently reported ADEs associated with aspirin use in COPD patients, thus offer valuable insights into the AEs of aspirin for safer clinical utilization in COPD management.
UNASSIGNED: We conducted a retrospective analysis of adverse drug events (ADEs) reported in the US Food and Drug Administration Adverse Event Reporting System (FAERS) between Q1 2013 and Q2 2022. COPD patients were categorized into two groups based on aspirin use. ADEs related to aspirin use were identified using combined reporting odds ratio (ROR), proportional reporting ratio (PRR), information component (IC) methods.
UNASSIGNED: A total of 56,660 ADEs reports associated with COPD patients were included in the study. Among these reports, 144 adverse events were linked to aspirin use in COPD patients, including fatigue (4.12%), diarrhea (3.13%), dyspnea exertional (2.03%), rhinorrhea (1.99%), weight increased (1.89%) and vomiting (1.84%), muscle spasms (1.79%), cardiac disorder (1.74%), heart rate increased (1.69%) and peripheral swelling (1.59%). Subgroup analysis indicates that age and gender might affect the AEs frequency in COPD patients using aspirin.
UNASSIGNED: Our findings identify 10 most frequently reported ADEs associated with aspirin use in COPD patients, thus offer valuable insights into the AEs of aspirin for safer clinical utilization in COPD management.
摘要：
■尽管阿司匹林在慢性阻塞性肺疾病（COPD）患者中具有潜在的益处和广泛的处方，有限的研究调查了其在COPD人群中的不良反应(AE)。
■我们对2013年第一季度至2022年第二季度美国食品和药物管理局不良事件报告系统（FAERS）报告的不良药物事件（ADE）进行了回顾性分析。COPD患者根据阿司匹林的使用分为两组。使用联合报告比值比(ROR)确定与阿司匹林使用相关的ADE，比例报告比率(PRR)，信息分量(IC)方法。
■本研究共纳入了56,660例与COPD患者相关的ADE报告。在这些报告中,144个不良事件与COPD患者使用阿司匹林有关，包括疲劳（4.12%），腹泻（3.13%），劳力性呼吸困难（2.03%），鼻漏（1.99%），体重增加（1.89%）和呕吐（1.84%），肌肉痉挛（1.79％），心脏疾病（1.74%），心率增加（1.69％）和外周肿胀（1.59％）。亚组分析表明，年龄和性别可能会影响使用阿司匹林的COPD患者的AE频率。
■我们的发现确定了COPD患者中与阿司匹林使用相关的10种最常报告的ADE，因此，为COPD管理中更安全的临床使用阿司匹林的AE提供有价值的见解。
■我们对2013年第一季度至2022年第二季度美国食品和药物管理局不良事件报告系统（FAERS）报告的不良药物事件（ADE）进行了回顾性分析。COPD患者根据阿司匹林的使用分为两组。使用联合报告比值比(ROR)确定与阿司匹林使用相关的ADE，比例报告比率(PRR)，信息分量(IC)方法。
■本研究共纳入了56,660例与COPD患者相关的ADE报告。在这些报告中,144个不良事件与COPD患者使用阿司匹林有关，包括疲劳（4.12%），腹泻（3.13%），劳力性呼吸困难（2.03%），鼻漏（1.99%），体重增加（1.89%）和呕吐（1.84%），肌肉痉挛（1.79％），心脏疾病（1.74%），心率增加（1.69％）和外周肿胀（1.59％）。亚组分析表明，年龄和性别可能会影响使用阿司匹林的COPD患者的AE频率。
■我们的发现确定了COPD患者中与阿司匹林使用相关的10种最常报告的ADE，因此，为COPD管理中更安全的临床使用阿司匹林的AE提供有价值的见解。
